key: cord-0270967-xa47iv6u
authors: Noel, Daniel J.; Keevil, C. William; Wilks, Sandra A.
title: Synergism vs Additivity - Defining the Interactions between Common Disinfectants
date: 2021-08-10
journal: bioRxiv
DOI: 10.1101/2021.08.09.455772
sha: d5b8d4a0fd76119b3e1008e2f81836b6678da65b
doc_id: 270967
cord_uid: xa47iv6u

Many of the most common disinfectant and sanitizer products are formulations of multiple antimicrobial compounds. Products claiming to contain synergistic formulations are common, although there is often little supporting evidence. The antimicrobial interactions of all pairwise combinations of common disinfectants (benzalkonium chloride, didecyldimethylammonium chloride, polyhexamethylene biguanide, chlorocresol and bronopol) were classified via checkerboard and validated by time-kill analyses. Combinations were tested against Acinetobacter baumannii NCTC 12156, Enterococcus faecalis NCTC 13379, Klebsiella pneumoniae NCTC 13443 and Staphylococcus aureus NCTC 13143. Synergistic interactions were only identified between cholorocresol with benzalkonium chloride, and chlorocresol with polyhexamethylene biguanide. Synergism was not ubiquitously demonstrated against all species tested and was on the borderline of the synergism threshold. These data demonstrate that synergism between disinfectants is uncommon and circumstantial. Most of the antimicrobial interactions tested were characterised as additive. We suggest that this is due to the broad, non-specific mechanisms associated with disinfectants not providing opportunity for the combined activities of these compounds to exceed the sum of their parts. IMPORTANCE The scarcity of observed synergistic interactions suggests that many disinfectant-based products may be misinterpreting combined mechanisms of interaction. We emphasise the need to correctly differentiate between additivity and synergism in antimicrobial formulations, as inappropriate classification may lead to unnecessary issues in the event of regulatory changes. Furthermore, we question the need to focus on synergism and disregard additivity when considering combinations of disinfectants, as the benefits that synergistic interactions provide are not necessarily relevant to the application of the final product.

of all pairwise combinations of common disinfectants (benzalkonium chloride, 27 didecyldimethylammonium chloride, polyhexamethylene biguanide, chlorocresol and 28 bronopol) were classified via checkerboard and validated by time-kill analyses. 29 Combinations were tested against Acinetobacter baumannii NCTC 12156, Enterococcus not ubiquitously demonstrated against all species tested and was on the borderline of the 34 synergism threshold. These data demonstrate that synergism between disinfectants is 35 uncommon and circumstantial. Most of the antimicrobial interactions tested were 36 characterised as additive. We suggest that this is due to the broad, non-specific mechanisms 37 associated with disinfectants not providing opportunity for the combined activities of these 38 compounds to exceed the sum of their parts. The scarcity of observed synergistic interactions suggests that many disinfectant-based 42 products may be misinterpreting combined mechanisms of interaction. We emphasise the 43 need to correctly differentiate between additivity and synergism in antimicrobial 44 formulations, as inappropriate classification may lead to unnecessary issues in the event of 45 regulatory changes. Furthermore, we question the need to focus on synergism and 46 disregard additivity when considering combinations of disinfectants, as the benefits that The central axiom that synergistic interactions can occur between antimicrobials with 70 different mechanisms of action and target sites has resulted in the liberal use of claims of 71 synergy when describing and marketing multi-component disinfectants products. 72 However, correctly classifying the type of interaction between antimicrobial agents is a 73 challenging process. For example, inconsistencies regarding the classification of an 74 antimicrobial interaction can arise depending on the method employed (4-7). lower the FICI value, the higher the level of interaction between the two tested compounds. 83 The checkerboard method provides a high-throughput technique that can yield a large 84 amount of information about how pairs of antimicrobials interact in a relatively short period 85 of time. Despite this the checkerboard method does raise significant challenges when it 86 comes to interpreting results and thus classifying antimicrobial interactions. Firstly, the 87 outcome of a checkerboard assay varies depending on the method of interpretation (8), 88 which is especially significant when many published articles do not explicitly state the 89 method of interpretation used. In addition, the FICI thresholds that can be set to define the 90 verdict of an interaction often vary between publications, creating issues around 91 standardisation and comparability of results. 92 Further complications arise when comparing data between species or strains, with 93 publications reporting significant variations in the classification of combined activities of 94 mixtures of both disinfectants (9, 10) and antibiotics (11, 12) . This has resulted in the same 95 combinations being reported as synergistic, additive or indifferent depending on the species 96 or even strain it was tested upon. While certain academic journals have implemented FICI 97 standards when reporting checkerboard data (13-15), these are not universally adhered to 98 between journals which further contributes to inconsistencies between publications. ). In the guidance to authors it is even suggested that alternative terms are used such as 113 "nonsynergistic" (15), thus encouraging researchers to disregard intermediate levels of 114 activity and focus exclusively on interactions that demonstrate synergy (15, 14) . This does 115 not mean that these journals completely disregard the existence of additive interactions, 116 instead that additivity is too difficult to pinpoint and identify reliably using the checkerboard 117 methodology. 118 The confusion between additivity and synergism and the methods employed to distinguish 119 between them has led to the two terms often being used interchangeably and potentially 120 erroneously. The confusion is especially significant as synergism in an antimicrobial 121 formulation is considered "surprising" and thus is patentable (3). This, alongside the 122 increased marketability the "synergy" buzzword brings, provides a commercial incentive to 123 classify such formulations as synergistic, even if the evidence is circumstantial and the 124 definitions are misunderstood. In addition, results that support patentable ideas often 125 remain unpublished in order to prevent potential loss of intellectual property. This means 126 that the evidence required to support a patent is not often subjected to the same scrutiny 127 as peer-reviewed publications. 128 These factors combined lead to academic and commercial-related research being "all or Table 1 , alongside their mechanisms of 134 action, applications and compounds they are commonly found with in formulations. 135 Previous research has indicated variability between species and strains (9-12), therefore 136 clinically-relevant bacterial species that display a degree of antibiotic resistance were 137 selected in order to provide a stringent test. In addition, strict activity classification 138 thresholds were used to provide clarity and to maintain consistency with the standards set 139 by leading journals in the field (13-15). Additivity was included as a classification due to the 140 context of the test. 141 

Minimum inhibitory concentration 146 The MIC results are summarised in Table 2 baumanii respectively and 20 µg/ml and 16 µg/ml for S. aureus and E. faecalis respectively. 158 The MIC for DMSO was greater than 100,000 µg/ml (10 % v/v) for all species tested (results 159 not shown). DMSO was therefore not responsible for the activity demonstrated by 160 chlorocresol. 161 Table 2 162 Checkerboard assay 163 The classification of interactions between pairs of disinfectants were evaluated via the 164 checkerboard method. Results are summarised in Table 3 Collectively, these factors could lead to the incorrect classification of a combined 219 antimicrobial activity. This is significant as it may result in consumers placing too much faith 220 in a product, leading to potential inappropriate and ineffective usage. The goal of this study 221 was to investigate the type of interaction between common disinfectants present in 222 formulations, and highlight current issues surrounding antimicrobial interaction testing. 223 The nature of the interactions between 5 common disinfectants when used in pairwise 224 combinations were classified via the widely used checkerboard method. The characteristics 225 of the antimicrobial compounds used in this study are summarised in Table 1. A synergistic   226 interaction between BAC and chlorocresol was observed against E. faecalis and S. aureus, 227 and between PHMB and chlorocresol against E. faecalis (Table 3 and Figure 1 ). These 228 combinations did not demonstrate synergism against A. baumanii or K. pneumoniae 229 however, indicating that this synergistic mechanism is species-specific. 230 These synergistic combinations were tested further via the time-kill methodology. The 231 antimicrobials combined resulted in a ≥5 log reduction in CFU/ml after 24 hours compared 232 to when they were used individually, confirming synergistic interactions (Figure 2) . 233 Indifference was observed in various combinations that contained bronopol, although it is 234 important to note that these indifferent interactions were not consistent across the species 235 tested (Table 3 and Figure 1 ). It has previously been reported that BAC and bronopol 236 synergistically inhibit sulfide production in sulfate-reducing bacteria (20). As antimicrobial 237 activity was measured via sulfide production it is difficult to draw comparisons between the 238 results. This variation between reports further demonstrates that disinfectant interactions 239 are not ubiquitous and vary in nature depending on the test species and methodologies 240 used. 241 Interestingly, it was observed that every combination of cationic membrane-active 242 antimicrobial (BAC, DDAC, PHMB) interacted additively across all species tested, with FICI 243 values ranging consistently between 0.54 and 1.00. This suggests that disinfectants with 244 similar mechanisms and cellular targets (see Table 1 ) consistently benefit from being in 245 combination, although not to the point of synergism. We propose that this is due to similar-246 acting compounds having a limited but consistent scope to complement each other's 247 activities when used in combination. At the sub-lethal concentrations tested, the cationic 248 membrane-active compounds both disrupt membrane stability and cause intracellular 249 leakage (21-23) thus will each mechanistically benefit from the presence of the other. With 250 broadly overlapping mechanisms the combined activity never has the opportunity to be 251 greater than the sum of its parts, therefore the interaction is limited to additivity. 252 Of the 40 test conditions tested, 30 demonstrated an additive interaction against the 253 respective target species (Table 3) mechanism that would enable a synergistic interaction. As a result, any combined activities 259 would simply be accumulative and would rarely ever be greater than the sum of its parts. 260 Thus the majority of the interactions observed are additive. We therefore postulate that 261 finding synergistic combinations of antimicrobials is more challenging when investigating 262 compounds that have non-specific, broad mechanisms (for example disinfectants) than 263 those that have more specific mechanisms of action (antibiotics). 264 Despite this observed scarcity in synergistic interactions, claims of synergy are common in 265 disinfectant products. It is possible that products may be being inappropriately classified as 266 synergistic due to the commercial incentives surrounding a "synergistic" claim combined 267 with non-peer-reviewed supporting data and a lack of understanding of the terminology. 268 Clarifying and identifying the differences between any additive and synergistic mechanisms 269 within a disinfectant formulation is of vital importance and should not be dismissed. (Table 3 ). In contrast, substituting an antimicrobial that provided an additive 289 interaction to a mixture can be achieved relatively easily via a functional analogue, as such 290 interactions are relatively common (Table 3) (Table 2) . Additionally, 306 there are many widely used disinfectants available that only contain one active component, 307 therefore demonstrating that combined antimicrobial interactions are not necessary for a 308 product to be effective and successful. 309 A second advantage of synergistic interactions is the ability to minimise resistance 310 development, as targets would have to become resistant to multiple distinct mechanisms 311 simultaneously (11, 32, 33). However, this benefit is not unique to synergistic interactions -312 it also applies to additive and even indifferent interactions too. Furthermore, resistance to 313 disinfectants at optimal concentrations is not a widespread issue that regularly impacts the 314 efficacy of products; thus it could be argued that this advantage is (currently) a moot point. 315 An additional advantage of a unique synergistic interaction is that it could enable 316 compounds to be effective against entirely new targets that they otherwise could not. 317 However, to our knowledge there is little evidence to demonstrate this occurring when 318 considering disinfectant combinations specifically. 319 With multiple academic journals not accepting additive interactions (13) the current bar is 320 set at distinguishing between synergistic interactions and everything else. However, 321 synergistic interactions do not necessarily provide any discernible advantages over additive 322 interactions when considering the quality and functionality of a disinfectant product. We 323 therefore question whether these standards are necessary and suggest that the focus 324 instead be shifted to distinguishing between additive and indifferent interactions when 325 assessing the combined activity of broad-spectrum disinfectants. 326 It is important to note that disinfectant products routinely contain more than two 'active' 

A synergistic interaction was characterised as demonstrating a ≥2 log 10 reduction in CFU/ml 432 between the combination and its most active constituent alone after 24 hours. In addition, 433 the number of CFU/ml must demonstrate a decrease of ≥ 2 log 10 CFU/ml below the starting 434 inoculum when exposed to the antimicrobial combination. 

Federal Insecticide, Fungicide, 444 and Rodenticide Act, 7 U.S.C. §136 et seq. 445 2. Council of the European Union

Theory of antimicrobial 449 combinations: Biocide mixtures -Synergy or addition?

Synergy testing by etest, microdilution checkerboard, and time-kill 452 methods for pan-drug-resistant Acinetobacter baumannii

Synergy tests by E test and checkerboard 455 methods of antimicrobial combinations against Brucella melitensis

Comparison of three different in 458 vitro methods of detecting synergy: Time-kill, checkerboard, and E test

Comparison of the checkerboard 461 and E-test methods used for the analysis of two antibiotics combination

Comparison of methods of 464 interpretation of checkerboard synergy testing

Evaluation of synergistic effects of three 467 bactericidal agents associated in an antiseptic formulation

Evaluation of antimicrobial 470 interactions between chlorhexidine, quaternary ammonium compounds, 471 preservatives and excipients

Synergistic combination of two 473 antimicrobial agents closing each other's mutant selection windows to prevent 474 antimicrobial resistance

A study on combination of daptomycin 476 with selected antimicrobial agents: In vitro synergistic effect of MIC value of 1 mg/L 477 against MRSA strains

Synergy, antagonism, and what the chequerboard puts between 479 them

Antimicrobial Agents and Chemotherapy -Instructions to Authors. Antimicrob 483 Agents Chemother

Terminology relating to methods for the determination of 485 susceptibility of bacteria to antimicrobial agents

In vitro evaluation of 487 the colistin-carbapenem combination in clinical isolates of a. baumannii using the 488 checkerboard, Etest, and time-kill curve Techniques

In-vitro evaluation of different antimicrobial combinations with and without colistin 492 against carbapenem-resistant Acinetobacter baumannii

In vitro activity of colistin in 494 combination with various antimicrobials against Acinetobacter baumannii species, a 495 report from South Iran

Synergistic inhibition of 497 microbial sulfide production by combinations of the metabolic inhibitor nitrite and 498 biocides

Antiseptics and Disinfectants: Activity, Action, and 500 Resistance

Mechanism of action of disinfectants

Domains in bacterial membranes and the action of 504 antimicrobial agents

Safety and Effectiveness of Consumer 506 Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use. 507 Final ruleFederal register

Safety and Effectiveness of Health Care Antiseptics

Topical Antimicrobial Drug Products for Over-the-Counter Human Use. Final rule

Letter from FDA CDER to Lonza America

American Cleaning Institute and Henkel North America regarding Review of 513

Letter from CDER FDA to American Cleaning 516

Food and Drug Administration

Food and Drug Administration. 2019. FINAL Third Extension Deferral Letter

Food and Drug Administration. 2020. Letter from FDA CDER to Lonza America

American Cleaning Institute and Henkel North America regarding Review of 523

Response from American Cleaning Institute to FDA 526 CDER (re: Benzalkonium Chloride)

The mutant selection window and antimicrobial resistance

Federal funding for the study of antimicrobial resistance in nosocomial 531 pathogens: No ESKAPE

Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

Standard -NinthMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria 537

That Grow Aerobically; Approved Standar-Ninth Edition

Comparison of the Action of Vantocil, Cetrimide 541 and Chlorhexidine on Escherichia coli and its Spheroplasts and the Protoplasts of 542

Gram Positive Bacteria

Effect of chlorhexidine diacetate and 544 benzalkonium chloride on the viability of wild type and envelope mutants of 545

Cationic antiseptics: Diversity of action under a common 547 epithet

Didecyldimethyl Ammonium Chloride, against 550 Staphylococcus aureus

Interaction of biologically active molecules 552 with phospholipid membranes

A study of the antibacterial activity of 554 some polyhexamethylene biguanides towards Escherichia coli ATCC 8739

Interaction of some 557 polyhexamethylene biguanides and membrane phospholipids in Escherichia coli

The antimicrobial polymer 561 PHMB enters cells and selectively condenses bacterial chromosomes. Sci Rep 6

Insights into the Polyhexamethylene Biguanide

Mechanism of Action on Bacterial Membrane and DNA: A Molecular Dynamics Study

Antibacterial Action of 2-Bromo-2-567

Nitropropane-1,3-Diol (Bronopol)

Bacterial target sites for biocide action

 437 This work was carried out by D. J. Noel as part of his Southampton NIHR Academy 438 Fellowship to fulfil PhD degree training funded by NIHR Southampton Biomedical Research